DefenCath (Taurolidine and Heparin)

DefenCath is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, used to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adults with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is used for use in a limited and specific group of patients.

Recommended Dosage: DefenCath is for instillation into central venous catheters (CVCs) only. It is not intended for systemic administration. Do not use this drug as a catheter lock flush product. Withdraw an ample volume of DefenCath catheter lock solution (CLS) from the vial using a sterile needle and syringe to fill the catheter lumens. Consider a 3mL or 5mL single-dose vial (on behalf of the volume of the catheter lumens) to instill medication into each catheter lumen after each HD session for patients with kidney failure requiring chronic HD. Before initiating the next HD session, DefenCath injection must be aspirated from the catheter and discarded. Each DefenCath single-dose vial is designed for use with a single patient as a single instillation in the central venous catheter (CVC). Discard any unused portion of the medicine remaining in the vial. 

• Heparin-induced thrombocytopenia (HIT) was noted at an incidence rate of 0.3 percent in Trial 1 in patients using heparin, a component of DefenCath injection, as a catheter lock solution (CLS). In case HIT occurs, discontinue treatment and institute suitable supportive measures.
  
• Drug hypersensitivity reactions were reported at an incidence rate of 0.5 percent in Trial 1 in all those using heparin, a component of the medication DefenCath, as a CLS. If a hypersensitivity reaction occurs, discontinue treatment and institute relevant supportive measures.
  
• Taurolidine/heparin is not intended for systemic administration. It is intended for use as a CLS in those with kidney failure requiring chronic hemodialysis; therefore, maternal use is not expected to result in fetal exposure to the medicine. Also, breastfeeding is not expected to cause exposure of the infant to the medicine.
  

What documents are required to import DEFENCATH to India?

DEFENCATH (taurolidine and heparin) can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

DEFENCATH (taurolidine and heparin) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of DefenCath in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of DEFENCATH (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for DefenCath price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug DefenCath®?

Taurolidine and heparin is a Generic Name for the trade name drug DefenCath®.

What is the Manufacturer’s Name of DefenCath®?

DefenCath® is manufactured by CorMedix Inc.

Is DefenCath® approved by the FDA?

Yes, DefenCath® is approved by the FDA. Date of first approval: November 15, 2023.

What is the dosage and form of DefenCath® supplied?

DefenCath® is supplied as a sterile, preservative-free, clear, aqueous-based solution with the following strengths: 

• 3 mL of catheter lock solution in a single-dose vial containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL) 
  
• 5 mL of catheter lock solution in a single-dose vial containing taurolidine 67.5 mg/5 mL (13.5 mg/mL), and heparin 5,000 USP Units/5 mL (1,000 USP Units/mL) 

The most common side effects of DefenCath® are nausea, hemodialysis catheter malfunction, bleeding, vomiting, musculoskeletal chest pain, dizziness, and thrombocytopenia.

How much does DefenCath® cost in India?

The cost of DefenCath in India can vary. To procure this combination medication legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of DefenCath®?

Each vial must be stored at a temperature of 20 to 25°C (68 to 77°F); excursions are permitted from 15 to 30°C (59 to 86°F). Do not freeze the medicine. Vials must be stored in the commercial carton, before the instillation in central venous catheters. 

Is it safe to buy DefenCath® online in India?

Yes, one can buy DefenCath online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of DefenCath® through legal channels.